Literature DB >> 29168272

Peanut oral immunotherapy dose variations do not result in allergic reactions.

Sara Anvari1,2, Daisy Tran1,2, Avina Nguyen1,2, Sridevi Devaraj3, Carla M Davis1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29168272     DOI： 10.1111/pai.12837

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  3 in total

1.  A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals.

Authors:  Sandra Andorf; Natasha Purington; Divya Kumar; Andrew Long; Katherine L O'Laughlin; Scott Sicherer; Hugh Sampson; Antonella Cianferoni; Terri Brown Whitehorn; Daniel Petroni; Melanie Makhija; Rachel G Robison; Michelle Lierl; Stephanie Logsdon; Manisha Desai; Stephen J Galli; Efren Rael; Amal Assa'ad; Sharon Chinthrajah; Jacqueline Pongracic; Jonathan M Spergel; Jonathan Tam; Stephen Tilles; Julie Wang; Kari Nadeau
Journal:  EClinicalMedicine       Date:  2019-01-21

Review 2.  Oral Immunotherapy (OIT): A Personalized Medicine.

Authors:  Francesca Mori; Simona Barni; Giulia Liccioli; Elio Novembre
Journal:  Medicina (Kaunas)       Date:  2019-10-13       Impact factor: 2.430

Review 3.  Transitioning peanut oral immunotherapy to clinical practice.

Authors:  S Lazizi; R Labrosse; F Graham
Journal:  Front Allergy       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.